A Study to Assess Patient Characteristics and Healthcare Resource Use (HCRU) Among COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
Study Details
Study Description
Brief Summary
The aim of this study is to describe the baseline demographic, clinical characteristics, and Healthcare Resource Use (HCRU) of adult (≥18 years) COVID-19 patients who have been prescribed nirmatrelvir, ritonavir treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID) Adult COVID-19 patients' HCRU within the 30-day period following nirmatrelvir, ritonavir prescription. |
Drug: nirmatrelvir, ritonavir
single cohort
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment: Age [Baseline]
- Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment: Gender [Baseline]
- Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment: Ethnicity [Baseline]
- Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment: Education [Baseline]
- Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment: Employment status [Baseline]
- Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment: Height [Baseline]
- Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment: Weight [Baseline]
- Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment: Body Mass Index (BMI) [Baseline]
- Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment: Smoking status [Baseline]
- Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment: Pre-existing Comorbidities [Baseline]
- Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment: Concomitant medications for comorbidities at index date [Baseline]
- Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment: Medications used to treat COVID-19 [Baseline]
- Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment: Previous COVID-19 infection during the last 6 months [Baseline]
Secondary Outcome Measures
- Assessment of Participants HRU: Inpatient setting [Within the 30-day period following nirmatrelvir, ritonavir prescription]
Days hospitalized, days in Intensive care unit (ICU) admission and length of stay.
- Assessment of Participants HRU [Within the 30-day period following nirmatrelvir, ritonavir prescription]
Yes/no questionnaire on outpatient visits, ER visits, supplemental oxygen use, vasopressor use, patient intubation.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Confirmed COVID-19 infection during the study observation period
-
Nirmatrelvir, ritonavir written prescription
Exclusion Criteria:
- None
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Saudi Arabia | Riyadh | Saudi Arabia |
Sponsors and Collaborators
- Pfizer
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- C4671054